Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses HAP Data, Informatics to AstraZeneca

NEW YORK, Dec. 11 - Genaissance Pharmaceuticals has given AstraZeneca access to specific HAP markers and its DecoGen informatics platform to help the pharmaceutical firm bolster its drug-discovery efforts, Genaissance said on Tuesday.


Financial or research details of the deal, the third of its kind that Genaissance has struck with a major pharmaceutical company, were not disclosed.


Genaissance, of New Haven, Conn., has a cache of almost 100,000 haplotypes from more than 5,400 genes and said it intends to discover haplotypes for all human genes.


"Pharmacogenomics has an expanding role to play in drug discovery and development," John Stageman, AstraZeneca's vice president of enabling science and technology, said in a statement. "AstraZeneca looks forward to using Genaissance's advanced HAP Technology platform and evaluating its potential to accelerate our internal efforts."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.